Drug Profile
A 337
Alternative Names: A337Latest Information Update: 28 Oct 2023
Price :
$50
*
At a glance
- Originator Evive Biotech
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action CD3 antigen stimulants; Epithelial cell adhesion molecule modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Oct 2023 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease) in World (IV, Infusion)
- 28 Sep 2022 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease) in Australia (IV, Infusion)
- 08 Sep 2020 Phase-I development is ongoing globally including Australia